Clinical trial NCT06939660: BCI-Assisted SCS-EXS for Gait Optimization
Official title: Spatiotemporal Spinal Cord Stimulation Based on Implantable Brain-machine Interfaces and Exoskeletons for Spinal Cord Injury (BASEGO)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Spinal Cord Injuries (SCI)
Spinal Cord Injury, Chronic
Spinal Cord Injury
Spinal Cord Injury Cervical
Spinal Cord Injury Thoracic
Spinal Cord Injury (Quadraplegia)
Motor Impairment
Motor Deficits
Gait Training
Gait Impairment
Keywords: Brain-computer interface
Spianl cord stimulation
Exoskeleton
Rehabilitation
Spinal cord injury
Motor dysfunction
BCI
Brain-spinal interface
BSI
Brain-machine interface
Gait training
Neural plasticity
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
Collaborators: name: Beijing Xinzhida Neural Technology Co., Ltd
name: Beijing Pins Medical Co., Ltd
name: Hangzhou RoboCT Technology Development Co.,Ltd
First posted: 2025-04-23
Enrollment: 3
Sex: ALL
Minimum age (years): 14
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the safety and technical feasibility of a novel brain-machine interface (BCI)-assisted spinal cord stimulation (SCS) and exoskeleton (EXS) system in patients with spinal cord injury (SCI). The primary aim is to determine whether the BCI-SCS-EXS system can safely and effectively improve lower limb motor function and quality of life in individuals with chronic SCI.

Participant Population:

Adults aged 14-65 years (sex/gender not limited). Patients with chronic SCI (≥6 months post-injury) classified as ASIA A, B, or C.

Individuals with stable health status, MMSE ≥22, and secondary education or above.

Primary Questions:

1. Is the BCI-SCS-EXS system safe and technically feasible for SCI rehabilitation?
2. Does the system improve lower limb motor function and quality of life in SCI patients?

Interventions:

Participants will undergo the following procedures:

Phase I (Implantation):

BCI implantation: ECoG electrodes placed over the motor cortex to decode lower limb movement intent.

SCS electrode implantation: 5-6-5 paddle electrodes at T11-L2 for targeted spinal cord stimulation.

Phase II (System Calibration):

BCI-SCS synchronization: Calibration of decoded motor intent to trigger SCS parameters.

SCS-EXO synchronization: Integration of SCS pulses with exoskeleton-assisted gait training.

Phase III (Rehabilitation):

Daily BCI-SCS-EXS training sessions (60 minutes, 5 times/week for 1 year). Adaptive adjustments to stimulation parameters and exoskeleton support based on performance.

Remote monitoring of device performance and emergency intervention for technical issues.

Outcome Measures:

Primary: Safety (adverse events, device performance, synchronization metrics). Secondary: Efficacy (motor function, neurophysiological function, quality of life).

Ethics and Safety:

Informed consent will be obtained from all participants. Adverse events will be monitored and reported according to CTCAE 5.0 guidelines.

Participant confidentiality will be strictly maintained. This study will provide foundational evidence for the safety and feasibility of the BCI-SCS-EXO system, paving the way for future randomized controlled trials in SCI rehabilitation.


Eligibility criteria: Inclusion Criteria:

* Age 14-65 years, any gender.
* Clinical diagnosis of spinal cord injury (SCI) due to trauma, inflammation, tumor, vascular disease, or iatrogenic factors, confirmed by medical history, physical examination, and ancillary tests, resulting in lower limb motor dysfunction.
* SCI diagnosed ≥6 months prior, with ≥1 month of continuous conventional rehabilitation (e.g., physical therapy, acupuncture, hydrotherapy, ≥3 hours daily) without significant improvement in motor function in the past 2 months.
* ASIA Impairment Scale (AIS) grade A, B, or C based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).
* Good general health with a life expectancy ≥12 months.
* Mini-Mental State Examination (MMSE) score ≥22.
* Educational attainment of secondary school or above.
* Willingness to participate, provide informed consent, and comply with study follow-up.

Exclusion Criteria:

* Presence of diseases other than spinal cord injury (SCI) that affect lower limb motor function, including brain diseases (e.g., brain tumor, stroke), lower limb vascular diseases (e.g., lower limb vascular occlusion), peripheral nerve diseases, or lower limb bone diseases (e.g., osteoarthritis, joint contracture).
* Requires continuous medical interventions (e.g., tracheal intubation, nasogastric feeding) to maintain critical physiological functions (e.g., heartbeat, respiration, swallowing).
* Congenital or acquired structural abnormalities of the lower limb bones or muscles.
* Presence of surgical contraindications (e.g., anesthesia-related adverse reactions, coagulation risks, or surgeon's determination of unsuitability for surgery).
* Presence of active implantable devices except for SCS or BCI devices (e.g., pacemakers, defibrillators, drug infusion pumps, cochlear implants, sacral nerve stimulators).
* Unable to receive implantable devices due to other disease treatments or investigations, or requires magnetic resonance imaging (MRI) during the device implantation period.
* MRI shows structural damage \>50% in motor function areas (precentral and postcentral gyri, ventromedial sensorimotor areas, mid temporal lobe, Broca's area, Wernicke's area, Geschwind's area), or DTI shows damage \>50% in the posterior limb of the internal capsule.
* Severe cardiovascular disease: Above level II myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥450 ms in men, ≥470 ms in women), level III-IV heart failure (NYHA classification), or echocardiography showing LVEF \<50%.
* Coagulation abnormalities (INR \>1.5 ULN, PT \>ULN +4 s, or APTT \>1.5 ULN), hemorrhagic tendency, or undergoing thrombolytic or anticoagulant therapy.
* Severe infections within 4 weeks before surgery (requiring IV antibiotics, antifungals, or antivirals) or lumbar soft tissue infections, or unexplained fever \>38.5℃ during screening or before surgery.
* HIV infection, acquired immunodeficiency syndrome (AIDS), active tuberculosis, active hepatitis B (HBV DNA ≥500 IU/ml), hepatitis C (positive HCV antibody and detectable HCV-RNA), or co-infection of hepatitis B and C.

Severe cerebrovascular events (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism within 12 months before enrollment.

* Metastatic malignancies or untreated malignant tumors.
* Major surgery or severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment.
* Addictive habits such as drug abuse or alcoholism.
* History of psychotropic drug abuse that is not controllable or presence of mental disorders, including major psychiatric illnesses (e.g., depression \[BDI score \>20\], anxiety, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorders, consciousness disorders).
* Pregnant, breastfeeding, planning to conceive, or women of childbearing potential without reliable contraception.
* Participation in other clinical trials within the past month.
* Cognitive impairments or poor compliance from subjects, family members, or caregivers, or inability to complete at least 12 months of follow-up and rehabilitation training.
* Other conditions that increase the risk of study participation or device use, as determined by the investigator.

Primary outcomes:
measure: The content and number of AEs as well as their severity according to CTCAE v6.0
timeFrame: 0-12 months post-implantation
Secondary outcomes:
measure: Signal Acquisition Normal Rate of BCI
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Electrode Impedance of BCI electrodes
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Effective Channel Count of BCI
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Electrode Impedance Stability of SCS
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Position Stability of SCS
timeFrame: 0, 3, 6, 12 months post-implantation
measure: Battery Fault Rate of SCS
timeFrame: 0-12 months post-implantation
measure: Command Trigger Success Rate of BCI-SCS Matching
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Delay Drift Deviation of BCI-SCS Matching
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Recognition Accuracy of BCI Brain Signal Decoding
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Latency of BCI Brain Signal Decoding
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Gait Trigger Delay of SCS-EXS Matching
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Joint Movement Consistency of SCS-EXS Matching
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Lower Limb Motor Score (LEMS)
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Muscle Strength of Lower Limbs
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Assisted Standing Time
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: 10-Meter Walk Test (10MWT)
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Gait Step Length
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Gait Joint Range
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Gait Symmetry
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Surface Electromyography (sEMG)
timeFrame: Time frame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Nerve Conduction Velocity
timeFrame: 0, 6, 12 months post-implantation
measure: Urodynamics
timeFrame: 0, 6, 12 months post-implantation
measure: SF-36 Health Survey
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: SCI-QOL Psychological Adaptation Subscale
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Cognitive Function by MMSE
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Cognitive Function by MoCA
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Pain Intensity
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
measure: Psychosocial Impact of Assistive Devices
timeFrame: 0, 1, 2, 3, 6, 12 months post-implantation
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital ,Capital Medical University
state: Beijing
Study officials:
References:
citation: Gad P, Gerasimenko Y, Zdunowski S, Turner A, Sayenko D, Lu DC, Edgerton VR. Weight Bearing Over-ground Stepping in an Exoskeleton with Non-invasive Spinal Cord Neuromodulation after Motor Complete Paraplegia. Front Neurosci. 2017 Jun 8;11:333. doi: 10.3389/fnins.2017.00333. eCollection 2017.
citation: Gorgey AS, Gill S, Holman ME, Davis JC, Atri R, Bai O, Goetz L, Lester DL, Trainer R, Lavis TD. The feasibility of using exoskeletal-assisted walking with epidural stimulation: a case report study. Ann Clin Transl Neurol. 2020 Feb;7(2):259-265. doi: 10.1002/acn3.50983. Epub 2020 Feb 5.
citation: Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7.
citation: Lorach H, Galvez A, Spagnolo V, Martel F, Karakas S, Intering N, Vat M, Faivre O, Harte C, Komi S, Ravier J, Collin T, Coquoz L, Sakr I, Baaklini E, Hernandez-Charpak SD, Dumont G, Buschman R, Buse N, Denison T, van Nes I, Asboth L, Watrin A, Struber L, Sauter-Starace F, Langar L, Auboiroux V, Carda S, Chabardes S, Aksenova T, Demesmaeker R, Charvet G, Bloch J, Courtine G. Walking naturally after spinal cord injury using a brain-spine interface. Nature. 2023 Jun;618(7963):126-133. doi: 10.1038/s41586-023-06094-5. Epub 2023 May 24.
citation: Liu P, Cheng Y, Xu Z, Li X, Chen Z, Duan W. Spatiotemporal spinal cord stimulation with real-time triggering exoskeleton restores walking capability: a case report. Ann Clin Transl Neurol. 2025 Mar;12(3):659-665. doi: 10.1002/acn3.52281. Epub 2024 Dec 15.